The JAG1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma cell line HT29, engineered for targeted disruption of the JAG1 gene. This loss-of-function model enables investigation of Jagged1-mediated Notch signaling in a well-characterized epithelial context. The heterogeneous knockout pool provides a population-level assessment of JAG1 deficiency, suitable for functional genomics, pathway dissection, and drug target validation without the clonal biases inherent in single-cell-derived lines.
The parental HT29 cell line, originally isolated from a 44-year-old female with colorectal adenocarcinoma, displays epithelial morphology with apical microvilli and retains the capacity to differentiate into enterocyte-like cells under appropriate conditions. HT29 cells are widely employed as an intestinal epithelial model for studying colorectal cancer biology, drug absorption, and barrier function. Their genetic background, including mutations in APC and TP53, makes them a relevant platform for exploring oncogenic signaling networks and therapeutic responses.
JAG1 encodes the transmembrane ligand Jagged1, a canonical activator of NOTCH receptors (NOTCH1?C4). Upon ligand-receptor interaction, ADAM10/ADAM17-mediated shedding and PSEN1/gamma-secretase cleavage release the NOTCH intracellular domain (NICD), which translocates to the nucleus, forms a transcriptional complex with RBPJ and MAML1, and drives expression of target genes such as HES1, HEY1, MYC, and CCND1. Jagged1 signaling is regulated by upstream factors including TP63, NF-??B, TGF-??, and HIF1A, and it crosstalks with Wnt and TGF-?? pathways. Downstream, NICD controls cell fate decisions by modulating proliferation, differentiation, apoptosis, and epithelial-to-mesenchymal transition (EMT). Interacting partners such as MIB1, DTX1, and NUMB fine-tune ligand activity and receptor endocytosis.
In HT29 colorectal cancer cells, NOTCH signaling sustains stemness, chemoresistance, and invasive properties. JAG1 knockout disrupts ligand-dependent NOTCH activation, attenuating NICD-mediated transcription and providing a tool to dissect the contribution of Jagged1 to these malignant phenotypes. This polyclonal knockout model is particularly valuable for studying the role of Jagged1 in tumor microenvironment interactions, angiogenesis, and maintenance of cancer stem cell populations. It also serves as a platform to evaluate therapeutic strategies targeting the NOTCH pathway, including gamma-secretase inhibitors and blocking antibodies.
Researchers can employ this knockout product in a broad spectrum of applications, from basic mechanistic studies to translational oncology. Typical assays include Western blotting, RT-qPCR, and luciferase reporter assays to monitor NOTCH transcriptional activity, immunofluorescence and flow cytometry to assess receptor expression, and functional assays such as migration, invasion, apoptosis, and drug sensitivity testing. The cells are also suitable for 3D culture and organoid models. For additional details or technical support, please contact Ascent Research.
